DiaMedica Therapeutics' Q3 net loss widens

DiaMedica Therapeutics

12/11/2025 21:40

Overview

DiaMedica Q3 net loss and EPS missed analyst expectations

Cash and investments increased to $55 mln, providing runway into 2H 2027

Outlook

Company anticipates cash runway into 2H 2027

Result Drivers

R&D EXPENSES - Increased due to progress in ReMEDy2 trial and Phase 2 IST in preeclampsia

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Miss
-$0.17
-$0.16 (3 Analysts)
Q3 Net Income
Miss
-$8.62 mln
-$8.13 mln (3 Analysts)
Q3 Operating Income
Miss
-$9.03 mln
-$8.33 mln (3 Analysts)
Q3 Cash & Investments
$55.30 mln
Q3 Pretax Profit
-$8.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $12.00, about 46.8% above its November 11 closing price of $6.39

Press Release: ID:nBw6rH4lka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)